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Summary
Background Many countries have shown marked declines in diarrhoeal disease mortality among children younger 
than 5 years. With this analysis, we provide updated results on diarrhoeal disease mortality among children younger 
than 5 years from the Global Burden of Diseases, Injuries, and Risk Factors Study 2017 (GBD 2017) and use the 
study’s comparative risk assessment to quantify trends and effects of risk factors, interventions, and broader 
sociodemographic development on mortality changes in 195 countries and territories from 1990 to 2017.
Methods This analysis for GBD 2017 had three main components. Diarrhoea mortality was modelled using vital 
registration data, demographic surveillance data, and verbal autopsy data in a predictive, Bayesian, ensemble 
modelling tool; and the attribution of risk factors and interventions for diarrhoea were modelled in a counterfactual 
framework that combines modelled population-level prevalence of the exposure to each risk or intervention with the 
relative risk of diarrhoea given exposure to that factor. We assessed the relative and absolute change in diarrhoea 
mortality rate between 1990 and 2017, and used the change in risk factor exposure and sociodemographic status to 
explain differences in the trends of diarrhoea mortality among children younger than 5 years.
Findings Diarrhoea was responsible for an estimated 533 768 deaths (95% uncertainty interval 477 162–593 145) 
among children younger than 5 years globally in 2017, a rate of 78·4 deaths (70·1–87·1) per 100 000 children. 
The diarrhoea mortality rate ranged between countries by over 685 deaths per 100 000 children. Diarrhoea mortality 
per 100 000 globally decreased by 69·6% (63·1–74·6) between 1990 and 2017. Among the risk factors considered in 
this study, those responsible for the largest declines in the diarrhoea mortality rate were reduction in exposure to 
unsafe sanitation (13·3% decrease, 11·2–15·5), childhood wasting (9·9% decrease, 9·6–10·2), and low use of oral 
rehydration solution (6·9% decrease, 4·8–8·4).
Interpretation Diarrhoea mortality has declined substantially since 1990, although there are variations by country. 
Improvements in sociodemographic indicators might explain some of these trends, but changes in exposure to risk 
factors—particularly unsafe sanitation, childhood growth failure, and low use of oral rehydration solution—appear to 
be related to the relative and absolute rates of decline in diarrhoea mortality. Although the most effective interventions 
might vary by country or region, identifying and scaling up the interventions aimed at preventing and protecting 
against diarrhoea that have already reduced diarrhoea mortality could further avert many thousands of deaths due to 
this illness.
Funding Bill & Melinda Gates Foundation.
Copyright © 2019 The Author(s). Published by Elsevier Ltd. This is an Open Access article under the CC BY 4.0 
license.
Introduction
Diarrhoeal diseases are the second leading infectious 
cause of mortality globally, after lower respiratory 
infections, among children younger than 5 years, 
although childhood mortality due to diarrhoea has 
declined since the 1990s.1–5 Accelerating and maintaining 
these declines is essential to meeting Sustainable 
Development Goals for under-5 childhood mortality and 
ensuring that children everywhere have the opportunity 
of a full, healthy life.
Many countries have shown marked declines in 
diarrhoea mortality among children younger than 5 years, 
and much of this progress has been associated with 
programmes addressing key environmental risks for 
diarrhoea and scaling up interventions to prevent or treat 
acute diarrhoea.3 Several global initiatives have offered 
guidance on efficient and recommended interventions to 
avert illness and mortality due to diarrhoea, including the 
Global Action Plan for Pneumonia and Diarrhea.6 These 
programmes have typically categorised interventions into 
groups that are defined by the stage in the morbidity 
pathway at which they occur, including prevention of 
infection (such as provision of safe water and sanitation) 
and treatment of disease (such as administration of 
oral rehydration solution).7 Studies have shown that 
rotavirus vaccine,8 safe water and sanitation,9,10 nutrition 
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supple mentation,10 and use of oral rehydration solution11 
protect children younger than 5 years against diarrhoea 
illness and mortality. However, no study to date has 
assessed the contribution of a range of risk factors and 
interventions on diarrhoea mortality across settings and 
over time.
We have previously shown a strong relationship 
between sociodemographic level and diarrhoea 
mortality2,3 but that does not necessarily translate 
to actionable evidence of interventions to prioritise 
to reduce health loss associated with diarrhoea. 
Understanding why some countries have seen more 
progress than others would provide such evidence and 
give a targeted roadmap for accelerating declines in 
diarrhoea mortality. The Global Burden of Diseases, 
Injuries, and Risk Factors Study 2017 (GBD 2017) is a 
systematic, scientific effort to quantify morbidity and 
mortality, including for diarrhoea and its risk factors.1,12,13 
With this analysis, we provide updated results of 
estimates of diarrhoea mortality among children 
younger than 5 years and use GBD’s comparative risk 
assessment to quantify trends and effects of risk 
factors, interventions, and broader sociodemographic 
development on mortality changes from 1990 to 2017. 
We use results from the GBD 2017 to assess which 
countries have performed best in reducing under-5 
diarrhoea mortality and compare countries on the basis 
of mortality rates, exposure to risk factors and 
interventions, and the contribution of changes in risk 
factor exposure to diarrhoea mortality.
Methods
Overview
Detailed methods for GBD and diarrhoea estimation in 
GBD have been previously published.1–3,12,13 Herein, we 
describe these methods briefly, focusing on a high-level 
description of modelling strategy. Further information 
about diarrhoea mortality modelling in GBD 2017 
is provided in the appendix (p 2). Uncertainty in 
the diarrhoea estimates is maintained through the 
modelling process using 1000 draws and is reflected 
as 2·5th and 97·5th percentiles of the posterior 
distribution. In compliance with the Guidelines for 
Accurate and Transparent Health Estimates Reporting,14 
data and code for the GBD 2017 cycle are publicly 
available.
This analysis had three main components: diarrhoea 
mortality estimation, diarrhoea risk factor and inter-
vention estimation, and the application of these results 
to evaluate changes in diarrhoea mortality between 
1990 and 2017. Although the GBD 2017 study also 
produced estimates of diarrhoea incidence, results 
are not presented here but can be found on the 
GBD-Compare website.
Research in context
Evidence before this study
The Global Burden of Diseases Study (GBD) has produced a 
series of updates to estimates of health loss due to over 
300 causes of death and disability, including diarrhoea. 
There are several other groups that also estimate diarrhoea 
mortality, particularly among children younger than 5 years, 
including the partnership between WHO and Maternal and 
Child Epidemiology Estimation. Although the estimates vary 
slightly between GBD iterations and compared with other 
groups’ estimates, one thing that is generally agreed on is that 
diarrhoea mortality among children younger than 5 years is 
decreasing over time. We searched PubMed from Jan 1, 2005, 
to April 29, 2019, with the search terms “diarrhea AND 
mortality AND global AND risk AND trend*” and found 
36 results, from which at least seven were using GBD results. 
This search found a few attempts to quantify the burden of 
individual risk factors, such as vitamin deficiency or 
breastfeeding, in a cross-sectional way; however, to our 
knowledge, no other study has attempted to evaluate trends in 
under-5 diarrhoea mortality over time due to demographic 
changes and changes in exposure to multiple risk factors.
Added value of this study
Here we report findings from GBD 2017, which builds on 
previous iterations of GBD with additional data and modelling 
improvements. We used estimates of 12 risk factors or 
interventions for diarrhoea mortality (handwashing, low 
rotavirus vaccine coverage, unsafe sanitation, unsafe water, 
zinc deficiency, childhood stunting, childhood underweight, 
childhood wasting, low use of oral rehydration solution, low 
birthweight and short gestation, suboptimal breastfeeding, 
and vitamin A deficiency), produced for the GBD study, 
to evaluate changes in diarrhoea mortality among children 
younger than 5 years. A major component of the GBD study is 
producing internally consistent and externally comparable 
estimates for all locations and over time, which allows us to 
identify countries where the diarrhoea mortality rate has 
changed the most and to evaluate the contributing risk factors 
or interventions that affect the mortality rate. We provide 
cross-sectional and longitudinal estimates of the reasons for 
which children are dying from diarrhoea, how these reasons 
vary, and where specific interventions might have the greatest 
impact.
Implications of all the available evidence
Diarrhoea mortality among children younger than 5 years has 
declined in many parts of the world, particularly because of 
improvements in safe sanitation, childhood nutrition, and use 
of oral rehydration solution. However, there is variation by 
country, suggesting that there is no single solution to reduce 
diarrhoea mortality. Every country must consider their specific 
context to identify strategies to reduce diarrhoea mortality. 
Our estimates can help provide evidence to do so.
See Online for appendix
For data and code for GBD 2017 
see http://ghdx.healthdata.org/
gbd-2017
For the GBD-Compare website 
see https://vizhub.healthdata.
org/gbd-compare/
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Deaths 
(95% UI)
Mortality rate 
per 100 000 
(95% UI)
Percent 
change in 
mortality rate 
(95% UI), 
1990 to 2017
Absolute 
difference in 
mortality rate 
per 100 000 
(95% UI), 
1990 to 2017
Deaths per 
100 000 
episodes 
(95% UI)
Attributable 
fraction for 
nutrition-
associated risks 
(95% UI)
Attributable 
fraction for 
low rotavirus 
vaccine 
coverage 
(95% UI)
Attributable 
fraction for 
unsafe WASH 
(95% UI)
Attributable 
fraction low 
ORS coverage 
(95% UI)
Attributable 
fraction for 
all risks 
(95% UI)
Global 533 768 
(477 162 to 
593 145)
78·4 
(70·1 to 87·1)
–69·6% 
(–74·6 to –63·1)
–179·5 
(–207·1 to 
–149·2)
48·2 
(44·5 to 51·5)
88·5% 
(81·3 to 92·4)
22·0% 
(16·7 to 27·9)
94·0% 
(85·9 to 98·1)
57·7% 
(39·9 to 70·8)
99·4% 
(98·7 to 99·8)
Central Europe, 
eastern Europe, 
and central Asia
2395 
(1907 to 
3032)
8·6 
(6·8 to 10·8)
–78·6% 
(–83·2 to –72·8)
–31·4 
(–31·8 to –30·5)
6·5 
(6·5 to 6·6)
85·3% 
(75·4 to 90·8)
8·0% 
(5·0 to 12·2)
82·5% 
(66·8 to 93·3)
51·1% 
(33·7 to 65·0)
97·7% 
(95·4 to 99·1)
Central Asia 2187 
(1703 to 2812)
22·8 
(17·8 to 29·3)
–82·2% 
(–86·4 to –76·8)
–105·1 
(–108·4 to –100·5)
24·3 
(23·2 to 25·4)
86·2% 
(76·8 to 91·5)
6·5% 
(4·0 to 10·3)
85·0% 
(69·3 to 94·8)
50·5% 
(33·1 to 64·6)
98·3% 
(96·3 to 99·4)
Central Europe 70 
(61 to 82)
1·2 
(1·1 to 1·4)
–83·4% 
(–86·4 to –79·4)
–6·2 
(–7·0 to –5·6)
0·7 
(0·7 to 0·8)
79·1% 
(65·2 to 86·6)
28·6% 
(18·8 to 40·0)
47·0% 
(26·6 to 68·9)
58·7% 
(40·9 to 71·9)
90·4% 
(84·0 to 95·0)
Eastern Europe 138 
(122 to 154)
1·1 
(1·0 to 1·2)
–87·3% 
(–88·8 to –85·8)
–7·4 
(–7·9 to –7·0)
0·8 
(0·7 to 0·8)
74·5% 
(60·7 to 81·8)
31·4% 
(20·2 to 44·5)
62·2% 
(43·7 to 79·4)
56·3% 
(38·4 to 69·7)
92·2% 
(86·3 to 96·2)
High-income 706 
(618 to 769)
1·2 
(1·1 to 1·3)
–44·0% 
(–52·9 to –35·7)
–1·0 
(–1·1 to –0·9)
1·4 
(1·2 to 1·7)
69·3% 
(53·4 to 79·0)
10·6% 
(6·0 to 16·5)
19·6% 
(11·6 to 30·0)
57·1% 
(39·6 to 70·2)
77·0% 
(67·2 to 83·6)
Australasia 12 
(8 to 17)
0·7 
(0·5 to 0·9)
61·1% 
(–4·1 to 143·1)
0·3 
(0·1 to 0·4)
1·4 
(1·3 to 1·5)
66·8% 
(47·3 to 78·6)
4·1% 
(1·8 to 8·2)
22·3% 
(10·3 to 40·8)
56·9% 
(39·0 to 70·1)
75·6% 
(63·8 to 83·8)
High-income 
Asia Pacific
53 
(45 to 61)
0·7 
(0·6 to 0·8)
–43·5% 
(–56·0 to –28·5)
–0·5 
(–0·7 to –0·5)
0·9 
(0·8 to 1·0)
72·0% 
(55·8 to 81·0)
16·1% 
(10·3 to 23·2)
21·7% 
(10·3 to 40·3)
56·6% 
(38·5 to 69·8)
81·1% 
(70·4 to 87·9)
High-income 
North America
371 
(314 to 410)
1·7 
(1·5 to 1·9)
125·3% 
(76·4 to 164·1)
1·0 
(0·8 to 1·0)
3·3 
(2·7 to 3·8)
66·9% 
(50·4 to 77·7)
7·9% 
(3·8 to 13·6)
11·6% 
(7·1 to 17·9)
56·9% 
(39·1 to 70·2)
72·4% 
(61·5 to 79·8)
Southern Latin 
America
141 
(114 to 170)
2·8 
(2·2 to 3·3)
–83·4% 
(–87·1 to –79·0)
–13·9 
(–15·3 to –12·6)
0·9 
(0·9 to 0·9)
76·4% 
(61·2 to 85·2)
10·1% 
(5·2 to 16·7)
49·6% 
(26·5 to 74·4)
57·8% 
(40·2 to 71·6)
89·6% 
(82·3 to 95·2)
Western Europe 129 
(114 to 146)
0·6 
(0·5 to 0·7)
–25·0% 
(–44·2 to –6·8)
–0·2 
(–0·3 to –0·2)
0·9 
(0·8 to 1·0)
69·1% 
(52·5 to 79·1)
18·5% 
(11·9 to 26·8)
8·9% 
(5·1 to 15·0)
56·7% 
(39·0 to 70·0)
74·9% 
(63·5 to 81·6)
Latin America 
and Caribbean
9904 
(8527 to 
11 490)
19·5 
(16·7 to 22·6)
–90·0% 
(–91·5 to –88·1)
–175·6 
(–185·4 to 
–165·7)
10·4 
(9·8 to 10·9)
79·4% 
(65·6 to 87·3)
8·0% 
(4·9 to 12·1)
82·0% 
(67·5 to 92·1)
55·7% 
(37·6 to 69·1)
96·2% 
(92·6 to 98·5)
Andean Latin 
America
754 
(560 to 1 003)
11·2 
(8·4 to 15·0)
–94·5% 
(–96·0 to –92·4)
–193·7 
(–227·1 to –163·8)
5·6 
(4·8 to 6·5)
70·4% 
(53·3 to 81·4)
5·1% 
(2·7 to 8·7)
77·0% 
(54·8 to 91·3)
60·3% 
(42·0 to 73·0)
93·5% 
(86·7 to 97·7)
Caribbean 3513 
(2358 to 5044)
89·8 
(60·3 to 128·9)
–72·4% 
(–82·1 to –57·9)
–236·1 
(–262·3 to –212·3)
48·1 
(40·2 to 55·6)
83·9% 
(70·9 to 91·2)
6·9% 
(4·4 to 10·0)
95·8% 
(88·9 to 98·9)
53·7% 
(35·3 to 67·7)
99·5% 
(98·6 to 99·9)
Central Latin 
America
3781 
(3269 to 
4428)
15·6 
(13·5 to 18·3)
–89·9% 
(–91·4 to –88·0)
–138·4 
(–143·5 to –132·7)
7·1 
(6·8 to 7·5)
76·3% 
(62·5 to 84·9)
10·5% 
(6·3 to 16·3)
74·4% 
(55·8 to 88·3)
58·7% 
(41·1 to 71·5)
94·6% 
(89·7 to 97·8)
Tropical Latin 
America
1856 
(1647 to 2087)
11·5 
(10·2 to 13·0)
–94·6% 
(–95·4 to –93·6)
–202·7 
(–225·0 to –178·9)
8·7 
(7·7 to 9·8)
79·8% 
(64·7 to 88·2)
2·2% 
(0·8 to 4·9)
73·6% 
(56·7 to 87·7)
51·7% 
(33·6 to 66·5)
94·5% 
(89·9 to 97·6)
North Africa 
and Middle 
East
28 962 
(23 106 to 
35 611)
45·0 
(35·9 to 55·3)
–80·7% 
(–84·8 to –75·3)
–188·5 
(–227·8 to 
–149·5)
17·9 
(16·7 to 18·7)
88·0% 
(78·6 to 92·8)
17·2% 
(11·0 to 25·1)
87·0% 
(74·9 to 94·9)
61·2% 
(43·6 to 73·6)
98·3% 
(96·5 to 99·4)
South Asia 135 390 
(115 688 to 
156 734)
77·6 
(66·3 to 89·9)
–81·4% 
(–85·8 to –76·1)
–339·4 
(–397·7 to 
–282·5)
74·8 
(71·6 to 
77·1)
89·6% 
(84·1 to 92·9)
16·9% 
(10·9 to 24·5)
92·9% 
(82·9 to 
97·9)
53·5% 
(36·1 to 
67·7)
99·6% 
(99·1 to 99·9)
Southeast Asia, 
east Asia, and 
Oceania
22 105 
(19 881 to 
24 679)
15·6 
(14·0 to 17·4)
–83·1% 
(–85·5 to 
–79·9)
–76·7 
(–88·6 to –65·6)
10·2 
(9·1 to 11·3)
88·1% 
(79·8 to 92·1)
29·5% 
(20·7 to 39·8)
85·7% 
(66·4 to 
95·6)
54·8% 
(37·1 to 
68·1)
98·6% 
(96·8 to 99·6)
East Asia 2645 
(2309 to 3198)
3·1 
(2·7 to 3·8)
–95·1% 
(–95·9 to –94·1)
–60·5 
(–70·9 to –52·3)
2·4 
(2·2 to 2·6)
77·3% 
(61·4 to 86·2)
9·9% 
(4·5 to 19·7)
77·4% 
(58·2 to 91·2)
55·5% 
(37·8 to 68·7)
95·1% 
(89·8 to 98·2)
Oceania 1450 
(961 to 2127)
81·5 
(54·0 to 119·6)
–37·3% 
(–60·7 to 0·0)
–48·5 
(–52·2 to –41·3)
27·4 
(22·9 to 
31·9)
88·1% 
(80·5 to 93·0)
21·5% 
(13·9 to 31·0)
94·8% 
(86·7 to 98·6)
61·7% 
(44·0 to 74·5)
99·5% 
(98·8 to 99·9)
Southeast Asia 18 009 
(15 924 to 
20 389)
32·4 
(28·6 to 36·7)
–79·3% 
(–83·3 to –73·7)
–123·9 
(–152·3 to –96·8)
18·0 
(17·0 to 19·1)
89·5% 
(82·3 to 93·0)
33·3% 
(23·8 to 44·5)
86·2% 
(66·0 to 95·9)
54·1% 
(36·4 to 67·5)
99·0% 
(97·4 to 99·7)
(Table continues on next page)
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Mortality
Most causes of death in GBD 2017, including diarrhoea, 
are modelled with the Cause of Death Ensemble model 
(CODEm).1,15 This statistical tool is designed to create a 
wide variety of models using a covariate selection 
algorithm and then to weight these models on the basis 
of their out-of-sample predictive validity. These models 
are combined into an ensemble that predicts diarrhoea 
mortality by age, sex, year, and location from 1980 to 2017. 
The model for diarrhoea uses vital registration data, 
demographic surveillance data, and verbal autopsy data. 
Covariates include childhood undernutrition, safe water 
and sanitation, the Socio-demographic Index (SDI), and 
maternal education, among others.1 SDI is a composite 
measure of development that accounts for fertility, 
education, and income and is associated with many 
population health indicators, including diarrhoea 
mortality.2
Risk factors
Risk factors in GBD 2017 are causally related to diarrhoea 
incidence or mortality.13 There are 12 risk factors or 
interventions for diarrhoea estimated in GBD 2017 (no 
handwashing with soap, low rotavirus vaccine coverage, 
unsafe sanitation, unsafe water, zinc deficiency, childhood 
stunting, childhood underweight, childhood wasting, low 
use of oral rehydration solution, low birthweight and short 
gestation, suboptimal breastfeeding, and vitamin A 
deficiency; details for their estimation are included in the 
appendix pp 7–57). In general, risk factors are part of a 
comparative risk assessment framework that involves a 
counterfactual approach to quantify the level of exposure 
to the risk factor in a population and the relative risk of 
diarrhoea given exposure. Typically, the exposure in a 
population is modelled on the basis of surveys and 
scientific literature and the risk of diarrhoea is from 
published meta-analyses or from systematic reviews done 
for GBD.13 For some risk factors in this analysis, notably 
unsafe water and sanitation, evidence of the risk of 
diarrhoea morbidity is assumed to represent the risk of 
diarrhoea mortality, because little or no data are available 
for mortality as the primary study outcome. More 
information on the modelling strategy for the risk factors 
can be found in the appendix (pp 10–53). We also used 
existing aggregate risk factors for childhood growth failure 
(ie, stunting, underweight, and wasting) and unsafe water, 
unsafe sanitation, and lack of access to handwashing 
with soap.13
Risk factors are counterfactual and estimated 
independently. For these reasons, the sum of risk-factor 
attributable fractions is not equal to 100% in a given 
population and could be more or less, depending on the 
population-level exposure to each factor. In other words, 
in this counterfactual approach, there are multiple 
potential ways to avert an episode of diarrhoea or prevent 
a death due to diarrhoea. For example, a child who dies 
from diarrhoea might have lacked adequate nutrition or 
safe water but access to either might have saved their life, 
even without access to the other.
Analysis of temporal trends
The last component of our analysis was the application 
of the results for diarrhoea-related mortality and 
risk factors to space and time patterns. The primary 
outcome of interest was the diarrhoea mortality rate per 
100 000 children younger than 5 years in 1990 and 2017. 
Deaths 
(95% UI)
Mortality rate 
per 100 000 
(95% UI)
Percent 
change in 
mortality rate 
(95% UI), 
1990 to 2017
Absolute 
difference in 
mortality rate 
per 100 000 
(95% UI), 
1990 to 2017
Deaths per 
100 000 
episodes 
(95% UI)
Attributable 
fraction for 
nutrition-
associated risks 
(95% UI)
Attributable 
fraction for 
low rotavirus 
vaccine 
coverage 
(95% UI)
Attributable 
fraction for 
unsafe WASH 
(95% UI)
Attributable 
fraction low 
ORS coverage 
(95% UI)
Attributable 
fraction for 
all risks 
(95% UI)
(Continued from previous page)
Sub-Saharan 
Africa
334 306 
(285 351 to 
388 790)
204·6 
(174·7 to 
238·0)
–68·4% 
(–74·2 to 
–60·3)
–443·0 
(–523·8 to –352·9)
91·3 
(91·0 to 
91·4)
88·5% 
(80·6 to 92·6)
24·4% 
(19·2 to 30·0)
96·2% 
(90·1 to 
99·0)
59·5% 
(41·7 to 72·4)
99·7% 
(99·1 to 99·9)
Central 
sub-Saharan 
Africa
34 800 
(25 798 to 
46 206)
176·1 
(130·6 to 233·9)
–63·5% 
(–73·9 to –49·3)
–306·9 
(–364·9 to –246·9)
59·5 
(52·6 to 67·7)
88·6% 
(79·2 to 93·4)
39·8% 
(32·0 to 47·2)
96·5% 
(91·2 to 99·1)
60·5% 
(42·2 to 73·4)
99·7% 
(99·2 to 99·9)
Eastern 
sub-Saharan 
Africa
98 175 
(84 620 to 
114 013)
155·1 
(133·7 to 180·1)
–70·3% 
(–76·4 to –62·3)
–367·1 
(–446·7 to –287·5)
72·2 
(69·7 to 75·4)
86·7% 
(78·5 to 91·2)
13·4% 
(8·7 to 19·0)
96·7% 
(91·2 to 99·2)
58·9% 
(41·1 to 71·5)
99·7% 
(99·1 to 99·9)
Southern 
sub-Saharan 
Africa
8 070 
(6 972 to 
9 314)
94·5 
(81·7 to 109·1)
–67·9% 
(–73·3 to –61·4)
–200·1 
(–223·6 to –173·6)
85·4 
(85·4 to 86·6)
81·5% 
(68·3 to 88·6)
7·1% 
(4·1 to 11·1)
89·0% 
(78·3 to 96·0)
53·2% 
(35·2 to 66·7)
98·3% 
(96·2 to 99·4)
Western 
sub-Saharan 
Africa
193 260 
(157 286 to 
236 075)
269·3 
(219·1 to 328·9)
–70·1% 
(–76·9 to –60·2)
–630·4 
(–785·7 to –480·1)
119·0 
(111·2 to 
126·9)
89·8% 
(82·2 to 93·6)
29·2% 
(23·7 to 35·0)
96·1% 
(89·9 to 99·0)
59·9% 
(41·0 to 72·9)
99·7% 
(99·2 to 99·9)
WASH=water, sanitation, and hygiene. ORS=oral rehydration solution. GBD=Global Burden of Diseases, Injuries, and Risk Factors Study. UI=uncertainty interval.
Table: Mortality from diarrhoeal diseases and associated risk factors by GBD super-region and region, 2017
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Figure 1: The diarrhoea mortality rate among children younger than 5 years by country, 1990 and 2017
Data are under-5 diarrhoea mortality rate (95% uncertainty interval) in 1990 (gray points) and in 2017 (coloured points). The colours indicate the Global Burden of 
Diseases, Injuries, and Risk Factors Study super region. Countries are ordered by increasing mortality rate in 2017.
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We calculated the absolute change in mortality rate as the 
difference between rates in 1990 and those in 2017. We 
calculated the relative percent change in mortality rate in 
2017 compared with 1990. We fitted a log-normal 
regression using SDI to predict the expected change in 
diarrhoeal mortality rate per unit increase in SDI. This 
rate was considered the baseline change in diarrhoeal 
mortality that is explained by changes in SDI.
To assess the effect of changes for each risk factor 
among children younger than 5 years, we took advantage 
of the counterfactual definition of risk factor burden such 
that the diarrhoea mortality rate due to each risk factor 
was equivalent to the reduction expected given complete 
absence of the risk factor. We categorised risk factors for 
diarrhoea mortality into two groups based on their 
biological mechanism of risk: prevention and protection. 
Prevention-associated risks are those that increase the 
probability of having diarrhoeal disease and include lack 
of rotavirus vaccine, no handwashing with soap, unsafe 
water, unsafe sanitation, and dietary zinc deficiency. 
Protection-associated risks are those that increase the 
likelihood of death among children with diarrhoea and 
include suboptimal breastfeeding, not receiving oral 
rehydration solution, low birthweight and short gestation, 
childhood stunting, childhood under weight, childhood 
wasting, and vitamin A deficiency (appendix pp 7–9). We 
decomposed the effect of the change in exposure to each 
risk factor on the diarrhoea mortality rate between 
1990 and 2017, accounting for the independent effects of 
population growth, population ageing, and other drivers 
of diarrhoea mortality. This process has been described in 
detail elsewhere.3,13
Role of the funding source
The funder of the study played no role in study design, 
data collection, data analysis, data interpretation, or 
writing of the report. All collaborators had full access to all 
the data in the study and the corresponding author had 
final responsibility for the decision to submit for 
publication.
Results
In 2017, diarrhoea was responsible for an estimated 
533 768 deaths (95% uncertainty interval [UI] 
477 162–593 145) among children younger than 5 years, 
globally (table), accounting for 9·9% (8·9–10·9) 
of all under-5 childhood deaths. Together, India 
(102 678 deaths, 87 608–118 510) and Nigeria (104 267 deaths, 
75 975–139 594) accounted for more than a third of all 
diarrhoea deaths (appendix pp 58–75). To increase the 
comparability of results across locations with radically 
different population sizes, the remaining results focus on 
mortality rate. Diarrhoea mortality rate among children 
younger than 5 years was 78·4 deaths (70·1–87·1) per 
100 000 children, globally, and ranged from 0·1 deaths 
(0·1–0·1) per 100 000 children in Singapore to 
685·8 (385·7–1082·0) per 100 000 children in the Central 
African Republic (Figures 1, 2A; appendix pp 58–75). The 
regions with the highest diarrhoea mortality rates were 
western sub-Saharan Africa (269·3 deaths, 219·1–328·9, 
per 100 000 children) and central sub-Saharan Africa 
(176·1 deaths, 130·6–233·9, per 100 000 children; table; 
figure 2A).
Diarrhoea mortality rate per 100 000 children decreased 
by 69·6% (95% UI 63·1–74·6) between 1990 and 2017, 
globally (table; figure 1). The greatest relative decline in 
diarrhoea mortality rate occurred in Saudi Arabia (98·1% 
decrease [95·9–99·1]; from 77·1 deaths [47·1–122·1] per 
100 000 children to 1·5 deaths [0·8–2·6] per 100 000 children; 
figure 1; appendix pp 58–75). Diarrhoea mortality rate 
increased in 25 countries (figure 2) but its absolute change 
in these locations was small during this time (table; 
figure 1). The greatest absolute decline in diarrhoea 
mortality rate occurred in Niger (1344·2 fewer deaths 
[969·9–1735·1] per 100 000 children between 1990 and 2017; 
from 1731·2 deaths [1223·8–2290·9] per 100 000 children in 
1990, to 387·8 deaths [253·9–555·9] per 100 000 children in 
2017; figures 1, 2C; appendix pp 58–75).
Nine countries (Armenia, China, Iran, Jamaica, 
Kazakhstan, Macedonia, Saudi Arabia, Turkey, and 
Uzbekistan) had mortality rates above the global median 
rate in 1990 and below the global median rate in 2017. 
These countries had steep increases in SDI during this 
time (appendix pp 91–93). Diarrhoea mortality rate 
decreased by 98·1% (95% UI 95·9–99·1) in Saudi Arabia, 
as reported above, by 98·0% (96·5–98·8) in Turkey 
(from 127·5 deaths [88·1–181·5] per 100 000 children 
to 2·6 deaths [1·7–3·7] per 100 000 children), and by 
95·5% (94·6–96·4) in China (from 65·0 deaths 
[56·3–75·9] per 100 000 children to 2·9 deaths [2·5–3·4] 
per 100 000 children). Some of these countries had 
diarrhoea mortality rates much lower than expected on 
the basis of SDI (appendix pp 58–75). For example, the 
ratio of observed-to-expected mortality rates in 
Armenia (0·17), Georgia (0·16), and Macedonia (0·12) 
were the three lowest globally, suggesting the mortality 
rate in these countries is much lower than expected 
based on SDI (figure 2D). By contrast, the ratios of 
observed-to-expected mortality rate in China (0·83) and 
Saudi Arabia (1·03) were closer to 1, suggesting a 
correlation between mortality rate and SDI in these 
locations. The observed mortality rate was much greater 
than expected based on SDI in some high-income 
Figure 2: Maps of diarrhoea mortality rate per 100 000 among children 
younger than 5 years, 1990–2017
(A) Diarrhoea mortality rate per 100 000 children younger than 5 years in 2017. 
(B) Relative percent difference and (C) absolute difference in diarrhoea mortality 
rate among children younger than 5 years between 2017 and 1990. (D) Ratio of 
observed-to-predicted diarrhoea mortality rate per 100 000 (predicted on the 
basis of the observed change in SDI between 1990 and 2017) in 2017. 
ATG=Antigua and Barbuda. FSM=Federated States of Micronesia. Isl=Islands. 
LCA=Saint Lucia. SDI=Socio-demographic Index. TLS=Timor-Leste. TTO=Trinidad 
and Tobago. VCT=Saint Vincent and the Grenadines.
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locations (eg, Canada [18·2] and Austria [12·4], which 
were the countries with the highest ratios, globally) as 
well as in low-income locations such as some countries 
in sub-Saharan Africa (eg, Equatorial Guinea [11·0], 
Central African Republic [5·8], and Sudan [4·7]; 
figure 2D).
The risk factors included in GBD 2017 for diarrhoea 
among children younger than 5 years accounted for 
99·4% (95% UI 98·7–99·8) of diarrhoea deaths in 2017 
(table; figure 3). Full use of the rotavirus vaccine could 
have prevented an estimated 22·0% (16·7–27·9) of 
diarrhoea deaths and providing safe water, sanitation, 
and hygiene (WASH) could have averted 94·0% 
(85·9–98·1) of deaths, globally (table; figure 3). Risk 
factors related to poor childhood nutrition, including 
growth failure and zinc and vitamin A deficiencies were 
responsible for 88·5% (81·3–92·4) of diarrhoea deaths 
in 2017, and full coverage of use of oral rehydration 
solution could have prevented 57·7% (39·9–70·8) of 
diarrhoea deaths in 2017 (table; figure 3). Poor childhood 
nutrition and unsafe WASH were attributed to a similar 
fraction of deaths (>75%) in most GBD super-regions, 
with the exception of the high-income super-region, 
where poor nutrition was responsible for 69·3% 
(53·4 to 79·0) and unsafe WASH for only 19·6% (11·6 to 
30·0) of deaths (table; figure 3). When grouped into 
quintiles, countries with the lowest SDI in 2017 had 
much greater risk attribution than countries in the 
highest SDI, particularly for unsafe WASH (96·5% 
[90·9–99·1] for countries in the lowest SDI vs 
13·0% [7·2–22·0] for countries in the highest SDI; 
appendix p 94).
A decomposition analysis of the percent change in 
diarrhoea mortality between 1990 and 2017 due to changes 
in risk factor attribution is shown in figure 4; countries are 
grouped by quintile of absolute decrease in diarrhoea 
mortality rate (from the largest decrease [5th quintile] to 
the smallest decrease [1st quintile]). Globally, factors 
responsible for the greatest reductions in the diarrhoea 
mortality rate were decreases in unsafe sanitation 
(13·3% decrease, 95% UI 11·2–15·5), childhood wasting 
(9·9% decrease, 9·6–10·2), and low use of oral rehydration 
solution (6·9% decrease, 4·8–8·4; figure 4; appendix 
pp 76–90).
Among the countries grouped in the 5th quintile 
(figure 4A), improvements in risk factors associated 
with undernutrition were correlated with the largest 
declines in diarrhoea mortality rate, including improve-
ments in childhood wasting (19·0% mean decrease, 
–15·0 to 47·8), childhood stunting (5·9% mean decrease, 
3·3 to 9·1), childhood underweight (5·5% mean 
decrease, 1·9 to 10·4), vitamin A deficiency (9·4% mean 
decrease, 4·1 to 15·6), and zinc deficiency (1·6% 
decreased attribution, –1·1 to 9·0). Expanded use of oral 
rehydration solution reduced diarrhoea mortality by 
7·1% (–1·6 to 18·1) on average in these countries 
Figure 3: Aggregated attributable fractions for diarrhoeal risk factors among children younger than 5 years by GBD super-region, 2017
In the comparative risk factors framework used in GBD 2017, risk factors are counterfactual and can overlap such that a single risk might be sufficient, but is not 
necessary, to cause a diarrhoea death. Therefore, although the total risk attribution cannot exceed 1, there could be overlap between the risk factors associated with 
rotavirus vaccine coverage, ORS treatment, nutrition, or WASH at the population level, such that eliminating exposure to one would avert a diarrhoea death. ORS=oral 
rehydration solution. WASH=water, sanitation, and hygiene.
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(figure 4A). The greatest improvements in childhood 
wasting were seen in Laos (55·2% decrease, 50·2–52·4) 
and Angola (53·9% decrease, 45·5–59·1; figure 4A). 
Many countries in this group greatly reduced diarrhoea 
mortality by expanding use of oral rehydration solution 
(eg, the greatest reduction was in Sierra Leone [24·5% 
decrease, 16·9–29·8]; figure 4A). Increased coverage of 
rotavirus vaccine reduced diarrhoea mortality rate by 
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substantial amounts among some countries that have 
introduced the vaccine, such as by 39·2% (22·4–73·7) in 
Burkina Faso and by 34·3% (19·3–63·2) in Togo 
(figure 4A). Among countries in this group, the decrease 
in diarrhoea mortality rate was not explained by large 
decreases in unsafe WASH exposures except for in a 
few countries, such as Equatorial Guinea and Egypt, 
where reductions in these risk factors substantially 
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reduced diarrhoea mortality rate (figure 4A; appendix 
pp 76–90).
Countries in the fourth quintile (second fastest) of the 
absolute change in diarrhoea mortality rate tended to 
have the decline mostly explained by WASH risks. 
For example, diarrhoea mortality rate decreased 
by 28·0% (95% UI 25·7–29·7%) in Indonesia and by 
21·8% (18·9–23·8) in India because of sanitation, by 
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39·2% (27·8–50·2) in Botswana because of increased 
access to safe water, and by 10·7% (4·8–16·2) in Bhutan 
because of handwashing (figure 4B; appendix pp 76–90). 
The mean change in diarrhoea mortality rate in these 
countries was more evenly explained by childhood growth 
failure, micro nutrition, and WASH risk factors than for 
countries in the third (figure 4C) and second (figure 4D) 
quintiles for reduction in diarrhoea mortality rate. China 
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Figure 4: Percent change in the diarrhoea mortality rate attributable to changes in risk factor exposure by country, grouped in quintiles of the absolute 
attributable change in mortality rate, 1990–2017
Data are percent reduction in diarrhoea mortality rate between 1990 and 2017 attributable to changes in exposure to each risk factor. The first row represents 
the value among all countries and the second row represents the mean value among countries in each country group: (A) 5th, (B) 4th, (C) 3rd, (D) 2nd, 
and (E) 1st quintile of the absolute attributable change in mortality rate between 1990 and 2017. The colours of the tiles indicate the quintile for the attributable 
change in mortality due to each risk factor among all countries. ORS=oral rehydration solution.
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and Saudi Arabia, two of three countries with the largest 
relative decline in diarrhoea mortality rate, were in the 
third quintile in absolute decline. A substantial amount 
of the decline in China was driven by improvements in 
handwashing (6·8%, 3·0–10·9), unsafe sanitation 
(20·6%, 19·4–21·0), and unsafe water (22·4%, 14·2–29·8; 
figure 4C). Countries in the first quintile, with the 
smallest absolute change in diarrhoea mortality rate, 
were mainly countries in the high-income GBD super-
region. The mortality rate increased because of increased 
prevalence of low birthweight and short gestational 
age in this quintile and by as much as 8·7% (8·3–10·3) 
in Singapore (figure 4E). Although improvements in 
rotavirus vaccine coverage, sub optimal breastfeeding, 
vitamin A deficiency, and moderate declines in stunting, 
underweight, and wasting contributed to reducing 
diarrhoea mortality in the Central African Republic and 
Zimbabwe, the net mortality rate increased in these 
two locations, potentially because of other unmeasured 
factors (241·4 additional deaths [114·6–430·5] per 
100 000 children in the Central African Republic and 
6·1 additional deaths [1·8–11·1] per 100 000 children in 
Zimbabwe; appendix pp 76–90). Overall, the diarrhoea 
mortality rate increased in 23 countries, most of which 
were in the GBD high-income super region (figure 4E; 
appendix pp 58–75).16
Discussion
Diarrhoea mortality among children younger than 
5 years is largely preventable with existing interventions 
that reduce exposure to pathogens and reduce the risk of 
mortality. Our estimates from this and previous iterations 
of GBD have consistently shown that diarrhoea is one of 
the leading causes of death in this age group.2,3 There is 
reason to be optimistic about the observed decline in 
mortality. But this trend should not lull public health 
officials, policy makers, and funding agencies into a 
sense that persistence of such declines is inevitable; 
rather, it should press all actors into asking why the pace 
of decline has been unequal across countries. The 
analyses presented here attempt to answer some of this 
most important question.
The SDI increased in every country between 
1990 and 2017.1 The greatest increase in SDI between 
1990 and 2017 occurred in Equatorial Guinea, a country 
where diarrhoea mortality decreased by more than 
550 deaths per 100 000 children during that time period. 
However, the two countries with the greatest absolute 
decline in diarrhoea mortality rates, Niger and Liberia, 
had increases in SDI that were smaller than the global 
average.1 The SDI indicator—a composite of income, 
education, and fertility—appears to be highly correlated 
with health outcomes but might struggle to capture rapid 
changes in living conditions within a country, such as the 
start or end of internal conflict. We have previously 
shown that the SDI is a strong predictor of diarrhoea 
mortality, but there are locations where difference 
between the mortality rate and the rate predicted on the 
basis of changes in SDI is large.2 An important contrast 
becomes apparent since the countries with the greatest 
relative decline in diarrhoea mortality rate (such as 
China, Turkey, and Saudi Arabia) appear to be correlated 
with increases in SDI, whereas the countries with the 
greatest absolute decline in diarrhoea mortality rate have 
declines that exceed those predicted by SDI. Increasing 
development is related to greater ability for countries to 
build and maintain integrative surveillance and treatment 
programmes. For example, starting in the early 1990s, 
China implemented a series of national programmes 
to reduce under-5 mortality, including the Program for 
Control of Diarrheal Diseases that focused on survei-
llance, health education, training, and access to health 
care for all counties, cities, and provinces with emphasis 
on rural areas.17
Regardless of distinguishing between relative and 
absolute change, countries with the largest declines in 
diarrhoea mortality rate tended to have large reductions 
in childhood underweight and stunting attribution. There 
have been substantial reductions in childhood growth 
failure from 1990 to 2017, but with persistent subnational 
variation.16 Our results show that improving the 
nutritional status of children is the single most important 
intervention to prevent infectious disease mortality. To a 
smaller extent, micronutrient deficiencies such as 
vitamin A and zinc deficiencies have improved in 
countries with either the fastest relative or absolute 
change. Childhood growth failure, including stunting, 
underweight, and wasting, appear to have a nearly linear 
relationship with SDI.13 The dietary zinc-deficiency risk 
factor reported in this Article is distinct from zinc therapy, 
which has been shown to substantially reduce diarrhoea 
duration and possibly mortality among children.18 
Diarrhoeal episodes among children are associated with 
impaired growth, and accounting for growth failure could 
increase the overall burden of diarrhoea by 40%.19,20 
Overall, given the range of additional health outcomes,21 
the efficacy,10 and the cost effectiveness of nutritional 
interventions, they should not be overlooked when 
considering strategies to reduce child vulnerability to 
diarrhoeal diseases.22
In the past two decades, researchers, policy makers, and 
clinicians have espoused the biologically plausible idea 
that reducing environmental contamination through 
WASH might be key to tackling the persistent challenge 
of childhood diarrhoea and stunting. However, at least 
three large trials10,23,24 have reported no effect of WASH 
combined interventions on child linear growth and 
showed little benefit due to safe water and mixed protective 
benefits for sanitation and handwashing for childhood 
diarrhoea. Although these studies focused on family-level 
or neighbourhood-level interventions, some evidence 
points to community-level contamination of water sources 
even when some members of the community are using 
safe water and sanitation or that household point-of-use 
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water purification interventions might be effective in such 
communities with high prevalence of unsafe sanitation.25 
Provision of universal safe water and sanitation requires 
substantial infrastructural, which might not be feasible in 
some locations.26,27 A 2018 report28 concluded that many 
countries are not on pace to meet targets for universal 
access to safe water and sanitation introduced in the 
Sustainable Development Goals. Poor access to safe water 
and sanitation persists particularly among rural and 
poor populations.28 Sanitation had the biggest effect 
on diarrhoea mortality among all risk factors (13·3% 
decrease, 95% UI 11·2–15·5), but this change appeared to 
be greatest in locations with middle values of SDI 
(0·4–0·6).13 Countries with the greatest relative change in 
diarrhoea mortality rate (such as China, Turkey, and Saudi 
Arabia) had steep reductions due to decreases in exposure 
to unsafe WASH. This trend was not observed among 
most of the countries with the fastest absolute reduction 
in diarrhoea mortality rate, where the change in attribution 
for the WASH risks were often in the lowest two quintiles 
of change among all countries.
Many countries have an SDI that is far from the range 
at which water and sanitation are likely to improve 
rapidly. Countries at the lower range of SDI that had the 
greatest declines in absolute mortality rates tended to 
succeed at reducing attribution to risks that act at the 
individual level. For example, some of the countries with 
the largest absolute declines in diarrhoea mortality rates 
(eg, Niger, Nigeria, Sierra Leone, and Somalia) had more 
than 15% reduction in diarrhoea mortality due to 
increased use of oral rehydration solution. Treatment 
with oral rehydration solution or with recommended 
home fluids is inexpensive and effective, perhaps 
explaining why oral rehydration solution decreased 
mortality in locations with a quite small change in SDI. 
Treatment with oral rehydration solution could prevent 
93% of diarrhoea deaths,11 but appropriate use remains 
low in many locations, perhaps because in some of these 
locations oral rehydration solutions are perceived as 
medication that must be prescribed by health-care 
workers (and hence might appear difficult to access), 
adherence to treatment is low, and alternative treatments 
(including antibiotics) are considered western medicine 
and thus are perceived as superior and preferentially 
used.29
Globally, 34·7% of under-5 diarrhoea deaths were 
caused by rotavirus.1 Existing rotavirus vaccines 
prevented about 30 000 deaths in 2016.30 Some of the 
poorest countries are eligible for support from Gavi, the 
Vaccine Alliance in funding rotavirus vaccine use but 
have not introduced the vaccine, such as the Democratic 
Republic of the Congo, Nigeria, Chad, and South Sudan.31 
These countries also had slower reductions in diarrhoea 
mortality than neighbouring countries that did introduce 
the vaccine, such as Rwanda, Niger, and Sudan. Countries 
in Latin America and the Caribbean were early adopters 
of the rotavirus vaccine and several countries have 
substantially reduced diarrhoea mortality due to 
rotavirus. There remains some uncertainty about the 
future of the rotavirus vaccine in low-to-middle SDI 
countries that have or will soon transition from being 
eligible for Gavi support. Introduction and coverage of 
the rotavirus vaccine, particularly among high-mortality 
countries, can avert a substantial amount of the diarrhoea 
deaths attributable to rotavirus.
There are several limitations in this study. Our 
estimates are dependent on data availability, which tends 
to be scarce, particularly among countries with high 
mortality in sub-Saharan Africa. Detailed, reliable, and 
timely data on disease burden are needed for countries to 
make informed decisions about health policy and 
interventions. Global burden estimates attempt to fill 
some of these gaps but have substantial uncertainty 
(which we have attempted to report consistently) and 
uncertainty is propagated through our modelling 
process. Previous criticism of the GBD diarrhoea 
estimates highlights both insufficient and conflicting 
data, including different requirements for using data on 
mortality and aetiologies. A principle of the GBD is to 
use all available, representative, and reliable data, which 
sometimes leads to global burden estimates based on 
different underlying data, a source of some differences 
between such estimates.32–34 For some risk factors, we 
assumed that the relative risk of diarrhoea episodes and 
diarrhoea mortality is the same. This assumption was 
necessary because of little or no data describing the risk 
of mortality but it is possible that such an assumption 
might have biased our estimates. Many of the covariates 
used in the mortality modelling are also inputs into the 
risk factor attribution as estimates of population-level 
exposure to those risks. The risks were included as 
covariates precisely because they affect diarrhoea 
mortality. The calculations for the relative risks are 
independent and do not influence the effect of the 
covariates in the diarrhoea mortality model.
Although we have quantified treatment with oral 
rehydration solution for diarrhoea, we did not explicitly 
account for health-care seeking behaviours, primary 
health-care availability, and other potential treatments 
like therapeutic zinc and antibiotic use. The comparative 
risk assessment framework used for risk factors in GBD 
estimates risk factors independently. Although this is 
essential for understanding the counterfactual disease 
burden associated with a risk, it means that we were 
unable to assess the potential of combined intervention 
strategies, such as those that target reductions in 
childhood underweight through breastfeeding promotion, 
and such intervention packages are likely to be very 
effective at reducing disease burden.35 We also know that 
there can be substantial overlap in exposure to risk factors 
such that an individual child might be both exposed 
to unsafe water and unvaccinated against rotavirus. 
Although we did not account for covariance in all risk 
factors, our approach does allow for the intuitive, 
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actionable interpretation that eliminating exposure to any 
attributable risk is sufficient to avert a diarrhoea death.
Evaluating trends and disease burden on the national 
level can mask subnational variation that exists because 
of different risk factor exposure, access to health care, or 
other factors. We have shown that childhood growth 
failure,16 diarrhoea mortality,5 and under-5 mortality4 are 
all geographically heterogeneous between and within 
countries in Africa. This analysis was done at a population 
level, which might hide individual exposures and 
behaviours. Future work evaluating risks and trends at 
fine geographical or individual levels and including 
correlations between risks at this level could better 
inform targeting of resources for interventions.
This study provides a clear and actionable path for 
reducing diarrhoea mortality among children younger 
than 5 years, but this path is likely to differ depending on 
location (including at a subnational level). Provision of 
oral rehydration solution for diarrhoeal episodes and the 
rotavirus vaccine have contributed to declines in even the 
poorest locations, whereas the provision of universal 
access to safe water and sanitation might require 
substantial infrastructural developments. Although less 
beneficial than some other interventions, vitamin A and 
zinc supplementation should be considered an essential 
part of routine childhood health care. Continuing to 
reduce diarrhoea mortality among children younger than 
5 years requires focused effort and intention. Assuming 
instead that these declines are inevitable, relying on the 
improvements expected with economic development is 
not enough; children are dying from diarrhoea now.
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